» Articles » PMID: 37328790

H-type Hypertension is a Risk Factor for Chronic Total Coronary Artery Occlusion: a Cross-sectional Study from Southwest China

Overview
Publisher Biomed Central
Date 2023 Jun 16
PMID 37328790
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic total coronary occlusion (CTO) is serious and the "last bastion" of percutaneous coronary intervention. Hypertension and hyperhomocysteinemia (HHCY) are synergistic and significantly increase cardiovascular event risk. The relationship between H-type hypertension and CTO remains unclear; thus, this cross-sectional study investigated this potential association.

Methods: Between January 2018 and June 2022, 1446 individuals from southwest China were recruited to participate in this study. CTO was defined as complete coronary artery occlusion persisting for over three months. H-type hypertension was defined as hypertension with plasma homocysteine levels ≥ 15 µmol/L. Multivariate logistic regression models were applied to assess the association between H-type hypertension and CTO. Receiver operating characteristic (ROC) curves were generated to determine the accuracy of H-type hypertension in predicting CTO.

Results: Of the 1446 individuals, 397 had CTO, and 545 had H-type hypertension. After multivariate adjustment, the odds ratio (OR) for CTO in individuals with H-type hypertension was 2.3-fold higher (95% CI 1.01-5.26) than that in healthy controls. The risk of CTO is higher in individuals with H-type hypertension than in those with isolated HHCY and hypertension. The area under the ROC curve for CTO was 0.685 (95% CI, 0.653-0.717) for H-type hypertension.

Conclusions: In southwest China, H-type hypertension is significantly related to the occurrence of CTO.

Trial Registration: This retrospective study was registered with the Chinese Clinical Trials Registry ( http://www.chictr.org.cn , ChiCTR2100050519.2.2).

References
1.
Liu J, Xu Y, Zhang H, Gao X, Fan H, Wang G . Coronary flow velocity reserve is impaired in hypertensive patients with hyperhomocysteinemia. J Hum Hypertens. 2014; 28(12):743-7. DOI: 10.1038/jhh.2014.22. View

2.
Zhang D, Wen X, Wu W, Xu E, Zhang Y, Cui W . Homocysteine-related hTERT DNA demethylation contributes to shortened leukocyte telomere length in atherosclerosis. Atherosclerosis. 2013; 231(1):173-9. DOI: 10.1016/j.atherosclerosis.2013.08.029. View

3.
McCully K . Melatonin, Hyperhomocysteinemia, Thioretinaco Ozonide, Adenosylmethionine and Mitochondrial Dysfunction in Aging and Dementia. Ann Clin Lab Sci. 2018; 48(1):126-131. View

4.
Zhang Q, Qiu D, Fu R, Xu T, Jing M, Zhang H . H-Type Hypertension and C Reactive Protein in Recurrence of Ischemic Stroke. Int J Environ Res Public Health. 2016; 13(5). PMC: 4881102. DOI: 10.3390/ijerph13050477. View

5.
Zhang Z, Gu X, Tang Z, Guan S, Liu H, Wu X . Homocysteine, hypertension, and risks of cardiovascular events and all-cause death in the Chinese elderly population: a prospective study. J Geriatr Cardiol. 2021; 18(10):796-808. PMC: 8558741. DOI: 10.11909/j.issn.1671-5411.2021.10.005. View